Welcome to our dedicated page for Micro Imaging Technology news (Ticker: MMTC), a resource for investors and traders seeking the latest updates and insights on Micro Imaging Technology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Micro Imaging Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Micro Imaging Technology's position in the market.
Micro Imaging Technology (OTC: MMTC) announced the acquisition of Cellmyx, a provider of aesthetic, cosmetic surgery and regenerative medicine tools. The deal complements the late-2025 acquisition of SaltMed/SaltFacial and is intended to support national and global product expansion.
Cellmyx focuses on autologous adipose grafting and transfer technologies for orthopedic, pain management and regenerative medicine. Its intelliFat BOD device received FDA 510(k) clearance in early 2023 for use in orthopedic, plastic and cosmetic surgery procedures using a patient’s own adipose tissue.